Gp96-Ig/costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T cell Priming and Enhances Immunity, Memory, and Tumor Elimination Heat Biologics 2017
Viagenpumatucel-L (HS-110) Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data From The DURGA Trial Heat Biologics 2016
In vivo Intratumoral Electroporation of Gp96-Ig/Fc-OX40L Stimulates CD8+ T cell Cross Priming to Tumor-Specific Neoantigens Heat Biologics 2016
Combination Immunotherapy: T-cell costimulation (OX40L, ICOSL, and 4-1BBL) secreted locally by Gp96-Ig vaccines, elicits robust antigenspecific, memory T cell responses and tumor elimination Heat Biologics 2016
Gp96-Ig/costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T cell Priming and Enhances Immunity, Memory, and Tumor Elimination Heat Biologics 2016
Combination Immunotherapy: T-cell costimulation (OX40L, ICOSL, and 4-1BBL) secreted locally by Gp96-Ig vaccines, elicits robust antigenspecific, memory T cell responses and tumor elimination Heat Biologics 2016
Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 co-stimulation for combination immunotherapy Heat Biologics 2016
Vector Engineered Immunotherapy Incorporating gp96-Ig and T Cell Costimulatory Fusion Proteins Elicits a Superior Antigen-Specific CD8+ T Cell Response Heat Biologics 2015
Immunotherapy meets epigenetics: Gp96-Ig cellular vaccine genetic signature is modulated by the inhibition of histone modifications Heat Biologics 2015
